

TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371

1012E-000300US

U.S. APPLICATION NUMBER: 097/868968

Not yet known

INTERNATIONAL APPLICATION NO.  
PCT/GB99/04382INTERNATIONAL FILING DATE  
23 December 1999PRIORITY DATE CLAIMED  
23 December 1998TITLE OF INVENTION TREATMENT AND DIAGNOSIS OF CANCER USING INOSITOLPHOSPHOGLYCANS  
ANTAGONISTS

APPLICANT(S) FOR DO/EO/US RADEMACHER, Thomas William

532 Rec'd PCT/PTO 22 JUN 2001

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
  - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☒ has been transmitted by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
  - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ have been transmitted by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☐ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

## Items 11. to 16. below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A FIRST preliminary amendment.  
☐ A SECOND or SUBSEQUENT preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information:
  - Verified Statement of Small Entity Status
  - Copy of IPER with Amendment under Article 34
  - Receipt Acknowledgement postcard
  - Certificate of Mailing

U.S. APPLICATION NO. 09/3468968

INTERNATIONAL APPLICATION NO.  
PCT/GB99/04382ATTORNEY'S DOCKET NUMBER  
1012E-000300US17. ☒ The following fees are submitted:**BASIC NATIONAL FEE** (37 CFR 1.492 (a) (1) - (5)) :

Neither international preliminary examination fee (37 CFR 1.482)  
nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO  
and International Search Report not prepared by the EPO or JPO ..... \$970.00

International preliminary examination fee (37 CFR 1.482) not paid to  
USPTO but International Search Report prepared by the EPO or JPO. .... \$840.00

International preliminary examination fee (37 CFR 1.482) not paid to USPTO but  
international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... \$760.00

International preliminary examination fee paid to USPTO (37 CFR 1.482)  
but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... \$670.00

International preliminary examination fee paid to USPTO (37 CFR 1.482)  
and all claims satisfied provisions of PCT Article 33(1)-(4) ..... \$96.00

**ENTER APPROPRIATE BASIC FEE AMOUNT** =**CALCULATIONS** PTO USE ONLY

Surcharge of **\$130.00** for furnishing the oath or declaration later than ☐ 20 ☐ 30  
months from the earliest claimed priority date (37 CFR 1.492(e)).

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total claims	22 - 20 =	2	X \$18.00	\$ 36.00
Independent claims	4 - 3 =	1	X \$80.00	\$ 80.00

MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$270.00

**TOTAL OF ABOVE CALCULATIONS** = \$ 956.00

Reduction of 1/2 for filing by small entity, if applicable. A Small Entity Statement  
must also be filed (Note 37 CFR 1.9, 1.27, 1.28). \$ 478.00

**SUBTOTAL** = \$ 478.00

Processing fee of **\$130.00** for furnishing the English translation later than ☐ 20 ☐ 30  
months from the earliest claimed priority date (37 CFR 1.492(f)).

**TOTAL NATIONAL FEE** = \$ 478.00

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be  
accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +

**TOTAL FEES ENCLOSED** = \$ 478.00

Amount to be:	\$
refunded	
charged	\$ 478.00

- a. ☐ A check in the amount of \$\_\_\_\_\_ to cover the above fees is enclosed.
- b. ☒ Please charge my Deposit Account No. 50-0893 in the amount of \$ 478.00 to cover the above fees.  
A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any  
overpayment to Deposit Account No. 50-0893. A duplicate copy of this sheet is enclosed.

**NOTE:** Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR  
1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Emily M. Haliday  
LAW OFFICES OF JONATHAN ALAN QUINE  
P.O. BOX 458  
Alameda, CA 94501  
United States of America

SIGNATURE

Emily M. Haliday

NAME

38,903

REGISTRATION NUMBER

Atty. Docket No. 1012B-000300US

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS**  
**(37 CFR 1.9(d) & 1.37(c)) - SMALL BUSINESS CONCERN**

Applicant or Inventor: Thomas William Rademacher, and Hugo Caro  
 Application or Patent No.: US National Phase Application of PCT/GB99/04382  
 Filed or Issued: December 23, 1999 (International Filing Date)  
 Title: TREATMENT AND DIAGNOSIS OF CANCER USING INOSITOL/PHOSPHOGLYCANS ANTAGONISTS

I hereby declare that I am:



the owner of the small business concern identified below  
 an official of the small business concern empowered to act on behalf of the concern identified below.

Name of Small Business Concern: Rademacher Group Limited  
 Address of Small Business Concern: 6 St. Andrew Street, London EC4A 3LX, United Kingdom

I hereby declare that the above-identified small business concern qualifies as a small business concern as defined in 13 CFR 121.12, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees to the United States Patent and Trademark Office, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention, entitled **TREATMENT AND DIAGNOSIS OF CANCER USING INOSITOL/PHOSPHOGLYCANS ANTAGONISTS** by inventor(s) Thomas William Rademacher and Hugo Caro described in:



the specification filed herewith,  
 Attorney Docket No. 1012B-000300US, filed 6/22/2001,  
 Patent No. \_\_\_\_\_ issued \_\_\_\_\_

If the rights held by the above identified small business concern are not exclusive, each individual, concern or organization having rights in the invention is listed below\* and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c) If that person made the invention, or by any concern that would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e).

\*NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averting to their status as small entities. (37 CFR 1.27)

Name \_\_\_\_\_  
 Address \_\_\_\_\_

☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

Name \_\_\_\_\_  
 Address \_\_\_\_\_

☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b)).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

Name of Person Signing: THOMAS RADEMACHER  
 Title of Person if Other than Owner: DIRECTOR  
 Address of Person Signing: Rademacher Group Limited, 6 St. Andrew Street, London EC4A 3LX, United Kingdom

Signature

Date

22/6/01

I hereby certify that this correspondence is being deposited with the United States Postal Service express mail in an envelope addressed to:  
 Assistant Commissioner for Patents Box PCT, Washington, D.C. 20231, on

6/22/01

LAW OFFICES OF JONATHAN ALAN QUINE

By:

*Deborah Bervich*

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Thomas William Rademacher; Hugo Caro

Examiner: Unknown

Application No.: Unknown

Art Unit:

Filed: 6/22/2001

For: **Treatment and Diagnosis of Cancer  
 Using Inositolphosphoglycans Antagonists**

**PRELIMINARY AMENDMENT**

Box PCT  
 Assistant Commissioner for Patents  
 Washington, D.C. 20231

Dear Sir:

Prior to calculating the claim fees, please amend the claims of the above-referenced application as indicated below.

**In the Claims:**

Please amend the claims by canceling claims 1-21 without prejudice and adding the following claims:

22. A method of reducing tumor cell proliferation comprising contacting a tumor cell with a substance which is an inositolphosphoglycan (IPG) antagonist having the property of reducing tumor cell proliferation.

23. The method of claim 22, wherein the tumor cell is in vivo in a subject and the substance is administered to the subject for the treatment of cancer.

24. The method of claim 22, wherein the IPG antagonist is:

(a) a substance which is capable of inhibiting the release of IPGs; or,

(b) a substance capable of reducing the levels of IPGs by binding to the IPGs; or,

(c) a substance which is a competitive agent which is capable of reducing an effect of IPGs.

25. The method of claim 24, wherein the IPG antagonist is a competitive IPG antagonist.

26. The method of claim 24, wherein the IPG antagonist is an anti-IPG antibody which is capable of specifically binding IPGs.

27. The method of claim 26, wherein the antibody is capable of neutralizing an activity of the IPGs.

28. The method of claim 27, wherein activity of the IPGs is the proliferation of tumor cells.

29. The method of claim 26, wherein the antibody is a monoclonal antibody produced by hybridoma 2F7, 2D1 or 5H6, deposited at ECACC under accession numbers 98051201, 98031212 and 98030901, respectively.

30. The method of claim 24, wherein the antagonist is an inhibitor of glycosylphosphatidylinositol specific phospholipase type C (GPI-PLC).

31. A method for the diagnosis and/or prognosis of cancer, the method comprising determining the presence or amount of inositolphosphoglycans in a sample from a patient.

32. The method of claim 31, wherein the presence or amount of the IPGs is causing tumor cell proliferation.

33. The method of claim 31, wherein the method comprises:

(a) contacting a sample from a patient with a solid support having immobilized thereon a binding agent having a binding site which is capable of specifically binding to the IPGs under conditions in which the IPGs bind to the binding agent; and,

(b) determining the presence or amount of the IPGs bound to the binding agent.

34. The method of claim 33, wherein step (b) comprises

(i) contacting the solid support with a developing agent which is capable of binding to occupied binding sites, unoccupied binding sites or the bound IPGs, the developing agent comprising a label, and (ii) detecting the label to obtain a value representative of the presence or amount of the IPGs in the sample.

35. The method of claim 34, further comprising comparing the value with standards from healthy or cancerous tissues.

36. The method of claim 34, wherein the label is selected from the group consisting of a radioactive label; a chemiluminescent label; a fluorophor; a phosphor; a laser dye; a chromogenic dye; a macromolecular colloidal particle; a latex bead which is coloured, magnetic or paramagnetic; and an enzyme which catalyses a reaction producing a detectable result.

37. The method of claim 33, wherein the binding agent immobilized on the solid support is an antibody which is capable of binding to the IPGs.

38. The method of claim 33, wherein the binding agent is immobilized at a predefined location on the solid support.

39. A method for purifying or isolating a P or A-type substance, wherein the substance is a cyclitol containing carbohydrate which is:

(i) a P-type substance having the biological activity of activating pyruvate dehydrogenase (PDH) phosphatase; or,

(ii) an A-type substance having the biological activity of inhibiting cAMP dependent protein kinase,

wherein the method comprises contacting a sample containing P or A-type substance with microcrystalline cellulose.

40. The method of claim 39, wherein the method involves contacting a sample containing P or A-type substance with a column containing cellulose and eluting the substance from the column.

41. A method of purifying or isolating a P or A-type substance, wherein the substance is a cyclitol containing carbohydrate which is:

(i) a P-type substance having the biological activity of activating pyruvate dehydrogenase (PDH) phosphatase; or,

(ii) an A-type substance having the biological activity of inhibiting cAMP dependent protein kinase; wherein the method comprises:

(a) loading a column containing microcrystalline cellulose with a sample containing the P or A-type substance so that P or A-type substance binds to the column; and,

(b) eluting the P or A-type substance from the column.

42. The method of claim 41, further comprising the step of dissolving the sample containing the P or A-type substance in 4/1/1 butanol/water/ethanol (B:W:E) prior loading on the column.

43. The method of claim 41, further comprising the step of washing the column with B:W:E and methanol.

These amendments are made without prejudice and are not to be construed as abandonment of the previously claimed subject matter.


REMARKS

Claims 22-43 are pending with entry of this amendment, claims 1-21 being cancelled and claims 22-43 being added herein. These amendments introduce no new matter.

Prompt examination of the above claims is respectfully requested. If a telephone conference would expedite prosecution of this application, the Examiner is invited to telephone the undersigned at (510) 337-8894.

LAW OFFICES OF JONATHAN ALAN QUINE  
P.O. BOX 458  
Alameda, CA 94501  
Tel: 510 337-7871  
Fax: 510 337-7877

Respectfully submitted,

  
Emily M. Haliday  
Reg. No: 38,903



TREATMENT AND DIAGNOSIS OF CANCER USING INOSITOLPHOSPHOGLYCANS ANTAGONISTSField of the Invention

The present invention relates to materials and methods for the treatment and diagnosis of cancer.

Background of the Invention

It has been observed that when tumour cells are grown in culture, the rate of proliferation of the cells depends on the cell density in the culture. It has been hypothesised that this increase in the rate of proliferation as the number of cells increases is due to the presence of tumour autocrine factors (TAFs) in the cell supernatant. TAFs are believed to be growth factors produced by the tumour cells which cause them to proliferate in the absence of external stimuli such as hormones.

There is some experimental evidence supporting the existence of TAFs in the culture supernatant. If the supernatant from a high density tumour cell culture is applied to a dilute culture, the rate of proliferation of the cells in the dilute culture quickly accelerates to the level associated with cells in a high density culture. It has also been observed that if the supernatant is boiled prior to addition to the dilute culture, the acceleration in the proliferation rate of the cells is not observed.

Witter et al (1987) have reported that conditioned medium from Reuber H-35 or Fao hepatoma cells contained autocrine factors that both stimulated DNA synthesis and activated acetyl-coenzyme A (CoA) carboxylase in serum deprived cells. They also found that the factors increased the cell number and mitotic index in tumour

cell cultures. The investigators fractionated conditioned medium from H-35 hepatoma cells and found that two low molecular weight components (MW < 1000) co-purified with the activity of increasing DNA synthesis. Radiolabelling incorporation studies suggested the possible incorporation of glucosamine and galactose, but no incorporation of *myo*-inositol or mannose. However, the authors were unable to purify, isolate or characterise the autocrine factor from conditioned medium and do not provide any definite suggestions as to the structure or activity of their autocrine factor.

### Summary of the Invention

Broadly, the present invention is based on the isolation and identification of TAFs, and in particular on the finding that TAFs are inositolphosphoglycans (IPGs) such as A or P-type IPGs. In particular, the results show that the TAFs include *myo*-inositol and by extension A-type IPGs.

Accordingly, in a first aspect, the present invention provides the use of a substance which is an IPG antagonist for the preparation of a medicament for the treatment of cancer. Preferably, the IPG antagonist has the property of reducing tumour cell proliferation.

In the present application, "IPG antagonists" includes substances which have one or more of the following properties:

(a) substances which are capable of inhibiting release of IPGs, e.g. inhibitors of enzymes which cause their release such as glycosylphosphatidylinositol specific phospholipases (GPI-PL);

(b) substances which are capable of reducing the levels of IPGs by binding to them, e.g. anti-IPG

antibodies, and preferably neutralising one or more IPG biological activities, more especially the activity of IPGs causing tumour cell proliferation; and/or,

(c) substances which are capable of reducing the effects of IPGs, e.g. competitive antagonists such as IPGs which are biologically inactive in the species in which they are used, e.g. the use of porcine liver A-type IPGs in humans.

In preferred embodiments, the IPG antagonist is an antibody capable of specifically binding IPGs and preferably which does not cross-react with the common reactive determinant of GPI anchored proteins. Preferably, the antibody is a monoclonal antibody, examples of which are disclosed below.

In other embodiments, the antagonist inhibits the release of IPGs. This suggests that an enzyme responsible for the release of the IPG TAFs is a GPI-PLC, which has not been previously identified in mammalian tissues. Therefore, inhibitors of GPI-PLC may be used as IPG antagonists for treatment of cancer.

In a further aspect, the present invention provides a method for the diagnosis or prognosis of cancer, the method comprising determining the presence or amount of IPGs in a sample from a patient. The presence or amount of IPGs in a given sample is typically then compared to standards from healthy and cancerous tissues.

Preferably, the presence or amount of the IPGs is determined by measuring a characteristic activity of an A or P-type IPG, details of which are set out below. Alternatively, the presence or amount of a characteristic component of IPGs and in particular IPG TAFs, could be

used as a diagnostic marker. Other components of IPGs that might be used as diagnostic markers are set out below.

5 In a further aspect, the present invention provides the use of cellulose column chromatography in the purification of IPGs.

10 In a further aspect, the present invention provides a method of purifying or isolating IPGs, the method comprising making contacting a sample containing IPGs with a column containing cellulose, and eluting the IPGs from the column. Preferred conditions preparing the column and eluting IPG containing fractions are set out  
15 below.

Embodiments of the present invention will now be described by way of example and not by limitation with reference to the accompanying figures.

#### Brief Description of the Figures

Figure 1 shows the fractionation of conditioned medium by cellulose column chromatography. The results are presented as counts per minute (cpm) per fraction. The  
25 arrows indicate the solvent system used at a particular fraction.

Figure 2 shows the effects on DNA synthesis of conditioned medium. Conditioned medium at two different  
30 concentrations (10% and 20%) was assayed for stimulating activity in test Fao cells. The results are presented as radioactivity (cpm) obtained after incorporation of  $^3\text{H}$ -thymidine into DNA, for control (no serum addition), FCS (5% foetal calf serum + 5% foetal bovine serum addition),  
35 and the fractions obtained. The arrows indicate the

eluent system used at a particular fraction.

Figure 3 shows phosphate analysis of conditioned medium fractionated by cellulose column chromatography. Results are presented as OD obtained per fraction. Arrows indicate the eluent system used at a particular fraction.

Figure 4 shows the effect on the proliferation of FaO cells of conditioned medium treated with anti-IPG monoclonal antibodies. Results are presented as radioactivity (cpm) obtained after incorporation of  $^3\text{H}$ -thymidine into DNA, for control (no serum addition), FCS (5% foetal calf serum + 5% foetal bovine serum addition), and samples containing the antibodies.

Figures 5 and 6 show rat liver IPGs A and P fractionation profiles. The results are shown as radioactivity (cpm) obtained after incorporation of  $^3\text{H}$ -thymidine into DNA of 3T3EFGTR17 cells, for control (no serum addition), FCS (10% foetal calf addition), and fractions. All fractions were assayed at a final IPG-A concentration of 1/80, except for fraction 26 of IPG-P (Fig. 5) which was also tested at a final concentration of 1/40 and 1/160. All fractions of the IPG-A (Fig. 6) were tested at a final concentration of 1/80. The arrows indicate the eluent system used at a particular fraction.

Figure 7 shows the phosphate analysis of rat liver IPG-P fractionated from rat liver by cellulose column chromatography. Results are presented as OD obtained per fraction. Arrows indicate the eluent system used at a particular fraction.

#### Detailed Description of the Invention

##### IPGs

Studies have shown that A-type mediators modulate the activity of a number of insulin-dependent enzymes such as cAMP dependent protein kinase (inhibits), adenylate cyclase (inhibits) and cAMP phospho-diesterases (stimulates). In contrast, P-type mediators modulate the activity of insulin-dependent enzymes such as pyruvate dehydrogenase phosphatase (stimulates), glycogen synthase phosphatase (stimulates) and cAMP dependent protein kinase (inhibits). The A-type mediators mimic the lipogenic activity of insulin on adipocytes, whereas the P-type mediators mimic the glycogenic activity of insulin on muscle. Both A-and P-type mediators are mitogenic when added to fibroblasts in serum free media. The ability of the mediators to stimulate fibroblast proliferation is enhanced if the cells are transfected with the EGF-receptor. A-type mediators can stimulate cell proliferation in the chick cochleovestibular ganglia.

Soluble IPG fractions having A-type and P-type activity have been obtained from a variety of animal tissues including rat tissues (liver, kidney, muscle brain, adipose, heart) and bovine liver. A- and P-type IPG biological activity has also been detected in human liver and placenta, RBC infected with *Plasmodium yoelii* and mycobacteria. The ability of an anti-inositolglycan antibody to inhibit insulin action on human placental cytotrophoblasts and BC3H1 myocytes or bovine-derived IPG action on rat diaphragm and chick cochleovestibular ganglia suggests cross-species conservation of many structural features.

A-type substances are cyclitol-containing carbohydrates, also containing  $Zn^{2+}$  ion and optionally phosphate and having the properties of regulating lipogenic activity

and inhibiting cAMP dependent protein kinase. They may also inhibit adenylate cyclase, be mitogenic when added to EGF-transfected fibroblasts in serum free medium, and stimulate lipogenesis in adipocytes.

P-type substances are cyclitol-containing carbohydrates, also containing  $Mn^{2+}$  and/or  $Zn^{2+}$  ions and optionally phosphate and having the properties of regulating glycogen metabolism and activating pyruvate dehydrogenase phosphatase. They may also stimulate the activity of glycogen synthase phosphatase, be mitogenic when added to fibroblasts in serum free medium, and stimulate pyruvate dehydrogenase phosphatase.

Methods for obtaining A-type and P-type IPGs are set out in Caro et al, 1997, and in WO98/11116 and WO98/11117. In summary, the methods disclosed in these applications involve:

(a) making an extract by heat and acid treatment of IPG source material;

(b) after centrifugation and charcoal treatment, allowing the resulting solution to interact overnight with an AG1-X8 (formate form) anion exchange resin;

(c) collecting a fraction having A-type IPG activity obtained by eluting the column with 50 mM HCl and/or collecting a fraction having P-type IPG activity obtained by eluting the column with 10mM HCl;

(d) adjusting to pH 4 (not to exceed pH 7.8) and lyophilising the fraction to isolate the substance;

(e) employing descending paper chromatography using 4/1/1 butanol/ethanol/water as solvent;

(f) purification using high-voltage paper electrophoresis in pyridine/acetic acid/water; and,

(g) purification using Dionex anion exchange chromatography or purification and isolation using Vydac

HPLC chromatography to obtain the isolated IPG.

As disclosed herein, it is also possible to employ column chromatography using cellulose, and especially microcrystalline cellulose, in the isolation or purification of IPGs. Exemplary conditions are provided in the experimental section below.

### **Antagonists**

In the present invention, "IPG antagonists" includes substances which have one or more of the following properties:

(a) substances which are capable of inhibiting release of IPGs, e.g. inhibitors of enzymes which cause their release such as GPI-PL;

(b) substances which are capable of reducing the levels of IPGs by binding to them and preferably neutralising an IPG biological activity; and/or,

(c) substances which are capable of reducing the effects of IPGs, e.g. competitive antagonists such as IPGs which are biologically inactive in the species in which they are used, e.g. the use of A-type IPGs as obtainable from porcine liver in humans.

Under (b) and (c), preferably the biological activity of the IPGs which is affected by the antagonists is the tumour cell proliferation caused by the IPGs when they are added to cell cultures. This can be readily determined using the assays described in the examples or other techniques well known to those skilled in the art.

Examples of IPG antagonists of type (b) include specific binding proteins, e.g. naturally occurring specific binding proteins that can be obtained by screening biological materials for substances that bind to IPGs.



In a further example, the antagonists are antibodies capable of specifically binding to IPGs. The production of polyclonal and monoclonal antibodies is well established in the art. Examples of anti-IPG monoclonal antibodies are produced by hybridoma cell lines 2F7, 2D1 and 5H6 deposited at European Collection of Cell Cultures (ECACC) under accession numbers 98051201, 98031212 and 98030901 on 12 May 1998 ('201) and 9 March 1998 ('212 and '901).

Monoclonal antibodies are particularly useful as they can be subjected to the techniques of recombinant DNA technology to produce other antibodies or chimeric molecules which retain the specificity of the original antibody. Such techniques may involve introducing DNA encoding the immunoglobulin variable region, or the complementarity determining regions (CDRs), of an antibody to the constant regions, or constant regions plus framework regions, of a different immunoglobulin. See, for instance, EP 0 184 187 A, GB 2 188 638 A or EP 0 239 400 A. A hybridoma producing a monoclonal antibody may be subject to genetic mutation or other changes, which may or may not alter the binding specificity of antibodies produced.

Antibodies may be obtained using techniques which are standard in the art. Methods of producing antibodies include immunising a mammal (e.g. mouse, rat, rabbit, horse, goat, sheep or monkey) with an immunogen, e.g. an IPG or a fragment thereof. Antibodies may be obtained from immunised animals using any of a variety of techniques known in the art, and screened, preferably using binding of antibody to antigen of interest. For instance, Western blotting techniques or immunoprecipitation may be used (Armitage et al, Nature,

357:80-82, 1992). Isolation of antibodies and/or antibody-producing cells from an animal may be accompanied by a step of sacrificing the animal.

5 As an alternative or supplement to immunising a mammal with an IPG, an antibody specific for the IPG may be obtained from a recombinantly produced library of expressed immunoglobulin variable domains, e.g. using lambda bacteriophage or filamentous bacteriophage which  
10 display functional immunoglobulin binding domains on their surfaces; for instance see W092/01047.

15 Antibodies according to the present invention may be modified in a number of ways. Indeed the term "antibody" should be construed as covering any binding substance having a binding domain with the required specificity. Thus, antagonist antibodies includes antibody fragments, derivatives, functional equivalents and homologues of antibodies, including synthetic molecules and molecules  
20 whose shape mimics that of an antibody enabling it to bind an antigen or epitope.

25 Examples of antibody fragments which capable of binding an IPG or other binding partner are the Fab fragment consisting of the VL, VH, C1 and CH1 domains; the Fd fragment consisting of the VH and CH1 domains; the Fv fragment consisting of the VL and VH domains of a single arm of an antibody; the dAb fragment which consists of a VH domain; isolated CDR regions and F(ab')<sub>2</sub> fragments, a  
30 bivalent fragment including two Fab fragments linked by a disulphide bridge at the hinge region. Single chain Fv fragments are also included.

35 Humanised antibodies in which CDRs from a non-human source are grafted onto human framework regions,

typically with the alteration of some of the framework amino acid residues, to provide antibodies which are less immunogenic than the parent non-human antibodies, are also included within the present invention and can be produced by the skilled person using techniques well known in the art.

A hybridoma producing a monoclonal antibody according to the present invention may be subject to genetic mutation or other changes. It will further be understood by those skilled in the art that a monoclonal antibody can be subjected to the techniques of recombinant DNA technology to produce other antibodies or chimeric molecules which retain the specificity of the original antibody. Such techniques may involve introducing DNA encoding the immunoglobulin variable region, or the complementarity determining regions (CDRs), of an antibody to the constant regions, or constant regions plus framework regions, of a different immunoglobulin. See, for instance, EP-A-184187, GB-A-2188638 or EP-A-0239400. Cloning and expression of chimeric antibodies are described in EP-A-0120694 and EP-A-0125023.

Hybridomas capable of producing antibody with desired binding characteristics are within the scope of the present invention, as are host cells, eukaryotic or prokaryotic, containing nucleic acid encoding antibodies (including antibody fragments) and capable of their expression. The invention also provides methods of production of the antibodies including growing a cell capable of producing the antibody under conditions in which the antibody is produced, and preferably secreted.

The antibodies described above may also be employed in the diagnostic aspects of the invention by tagging them

with a label or reporter molecule which can directly or indirectly generate detectable, and preferably measurable, signals. The linkage of reporter molecules may be directly or indirectly, covalently, e.g. via a peptide bond or non-covalently. Linkage via a peptide bond may be as a result of recombinant expression of a gene fusion encoding antibody and reporter molecule.

One favoured mode is by covalent linkage of each antibody with an individual fluorochrome, phosphor or laser dye with spectrally isolated absorption or emission characteristics. Suitable fluorochromes include fluorescein, rhodamine, phycoerythrin and Texas Red. Suitable chromogenic dyes include diaminobenzidine.

Other reporters include macromolecular colloidal particles or particulate material such as latex beads that are coloured, magnetic or paramagnetic, and biologically or chemically active agents that can directly or indirectly cause detectable signals to be visually observed, electronically detected or otherwise recorded. These molecules may be enzymes which catalyse reactions that develop or change colours or cause changes in electrical properties, for example. They may be molecularly excitable, such that electronic transitions between energy states result in characteristic spectral absorptions or emissions. They may include chemical entities used in conjunction with biosensors. Biotin/avidin or biotin/streptavidin and alkaline phosphatase detection systems may be employed.

In a further embodiment, the IPG antagonists are competitive antagonists, such as synthetic compounds or IPGs which are biologically inactive in the relevant respect, e.g. IPGs which do not have a TAF activity such

13

as enhancing the proliferation of tumour cells. An example of this latter type of antagonist is the use of porcine liver A-type IPGs in humans as described in GB-A-9828560.4 (WO00/38698) and related applications.

5 Synthetic compounds may be produced by chemical techniques or using combinatorial chemistry, and then screened for IPG antagonist activity. These compounds may be useful in themselves or may be used in the design of mimetics, providing candidate lead compounds for development as

10 pharmaceuticals. Synthetic compounds might be desirable where they are comparatively easy to synthesize or where they have properties that make them suitable for administration as pharmaceuticals, e.g. antagonist which are peptides may be unsuitable active agents for oral

15 compositions if they are degraded by proteases in the alimentary canal. Mimetic design, synthesis and testing is generally used to avoid randomly screening large number of molecules for a target property.

20 Pharmaceutical Compositions

IPGs or IPG antagonists can be formulated in pharmaceutical compositions. These compositions may comprise, in addition to one or more of IPGs or antagonists, a pharmaceutically acceptable excipient,

25 carrier, buffer, stabiliser or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient. The precise nature of the carrier or other material may depend on the route of

30 administration, e.g. oral, intravenous, cutaneous or subcutaneous, nasal, intramuscular, intraperitoneal routes.

Pharmaceutical compositions for oral administration may be

35 in tablet, capsule, powder or liquid form. A tablet

may include a solid carrier such as gelatin or an adjuvant. Liquid pharmaceutical compositions generally include a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil or synthetic oil.

5 Physiological saline solution, dextrose or other saccharide solution or glycols such as ethylene glycol, propylene glycol or polyethylene glycol may be included.

10 For intravenous, cutaneous or subcutaneous injection, or injection at the site of affliction, the active ingredient will be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability. Those of relevant skill in the art are well able to prepare  
15 suitable solutions using, for example, isotonic vehicles such as sodium chloride injection, Ringer's injection, lactated Ringer's injection. Preservatives, stabilisers, buffers, antioxidants and/or other additives may be included, as required.

20 Whether it is a polypeptide, antibody, peptide, small molecule or other pharmaceutically useful compound according to the present invention that is to be given to an individual, administration is preferably in a  
25 "prophylactically effective amount" or a "therapeutically effective amount" (as the case may be, although prophylaxis may be considered therapy), this being sufficient to show benefit to the individual. The actual amount administered, and rate and time-course of  
30 administration, will depend on the nature and severity of what is being treated. Prescription of treatment, e.g. decisions on dosage etc, is within the responsibility of general practitioners and other medical doctors, and typically takes account of the disorder to be treated,  
35 the condition of the individual patient, the site of

delivery, the method of administration and other factors known to practitioners. Examples of the techniques and protocols mentioned above can be found in Remington's Pharmaceutical Sciences, 16th edition, Oslo, A. (ed), 1980.

The compositions may be administered alone or in combination with other treatments, either simultaneously or sequentially dependent upon the condition to be treated. Thus, in the treatment of cancer, the IPG antagonists can be administered in combination with other chemotherapy or radiotherapy.

#### Diagnostic Methods

Methods for determining the concentration of analytes in samples from individuals are well known in the art and readily adapted by the skilled person in the context of the present invention to determine whether an individual has an elevated level of IPGs, and so has or is at risk of cancer. The purpose of such analysis may be used for diagnosis or prognosis to assist a physician in determining the severity or likely course of the cancer and/or to optimise treatment of it. Examples of diagnostic methods are described in the experimental section below.

Preferred diagnostic methods rely on the detection of IPGs, employing biological samples such as blood, serum, urine or tissue samples (especially from a suspected tumour site).

The assay methods for determining the concentration of IPGs typically employ a binding agent having binding sites capable of specifically binding to the IPGs in preference to other molecules. Examples of binding

agents include antibodies (examples of which are provided above), receptors and other molecules capable of specifically binding IPGs. Conveniently, the binding agent is immobilised on solid support, e.g. at a defined location, to make it easy to manipulate during the assay.

The sample is generally contacted with a binding agent under appropriate conditions so that IPGs present in the sample can bind to the binding agent.

The fractional occupancy of the binding sites of the binding agent can then be determined either by directly or indirectly labelling the analyte or by using a developing agent or agents to arrive at an indication of the presence or amount of the analyte in the sample. Typically, the developing agents are directly or indirectly labelled (e.g. with radioactive, fluorescent or enzyme labels, such as horseradish peroxidase) so that they can be detected using techniques well known in the art. Directly labelled developing agents have a label associated with or coupled to the agent. Indirectly labelled developing agents may be capable of binding to a labelled species (e.g. a labelled antibody capable of binding to the developing agent) or may act on a further species to produce a detectable result. Thus, radioactive labels can be detected using a scintillation counter or other radiation counting device, fluorescent labels using a laser and confocal microscope, and enzyme labels by the action of an enzyme label on a substrate, typically to produce a colour change. In further embodiments, the developing agent or analyte is tagged to allow its detection, e.g. linked to a nucleotide sequence which can be amplified in a PCR reaction to detect the analyte. Other labels are known to those skilled in the art are discussed below. The developing agent(s) can be



used in a competitive method in which the developing agent competes with the analyte for occupied binding sites of the binding agent, or non-competitive method, in which the labelled developing agent binds analyte bound by the binding agent or to occupied binding sites. Both methods provide an indication of the number of the binding sites occupied by the analyte, and hence the concentration of the analyte in the sample, e.g. by comparison with standards obtained using samples containing known concentrations of the analyte.

The sample is generally contacted with the binding agent under appropriate conditions which allow the analyte in the sample to bind to the binding agent.

There is also an increasing tendency in the diagnostic field towards miniaturisation of such assays, e.g. making use of binding agents (such as antibodies or nucleic acid sequences) immobilised in small, discrete locations (microspots) and/or as arrays on solid supports or on diagnostic chips. These approaches can be particularly valuable as they can provide great sensitivity (particularly through the use of fluorescent labelled reagents), require only very small amounts of biological sample from individuals being tested and allow a variety of separate assays can be carried out simultaneously. This latter advantage can be useful as it provides an assay employing a plurality of analytes to be carried out using a single sample. Examples of techniques enabling this miniaturised technology are provided in WO84/01031, WO88/1058, WO89/01157, WO93/8472, WO95/18376/ WO95/18377, WO95/24649 and EP 0 373 203 A. Thus, in a further aspect, the present invention provides a kit comprising a support or diagnostic chip having immobilised thereon a plurality of binding agents, at least one of which is

capable of binding to an IPG as described above, optionally in combination with other reagents (such as labelled developing reagents) needed to carrying out an assay.

## **Materials and Methods**

### **Anti-IPG Antibodies**

Anti-IPG antibodies were produced by culturing hybridoma cell lines 2F7, 2D1 and 5H6 deposited at European Collection of Cell Cultures (ECACC) under accession numbers 98051201, 98031212 and 98030901, and isolating the anti-IPG antibodies thus produced.

### **Cellulose Purification of IPGs**

Microcrystalline cellulose (Merck Avicel®) was fined by suspension in double-distilled water followed by standing for 10 minutes and decanting of the unsettled suspension. After 12 repeats, the settled material was shaken vigorously with two volumes of fresh water and poured into the top of a Pharmacia® glass column of 16 mm i.d. with the top plunger removed. Water was allowed to flow out under gravity at 3 ml/min. After allowing the solvent level to drop to the top of the packed bed, the plunger was replaced and water pumped through the column at 5 ml/min using a Pharmacia® peristaltic pump. The column was treated with the following solvents:

Water	150ml
50% aqueous methanol	50ml
Methanol	50ml
Butanol/methanol/water (4:1:1)	150ml

All solvents were degassed prior to use by brief swirling under vacuum. After the final solvent, the plunger was removed, and the solvent level allowed to drop to the top

of the packed bed under gravity, whereupon flow was stopped.

The sample (2 ml of conditioned cell medium or IPG extract from two rat livers) was swirled for 5 minutes with 2 ml of the cellulose suspension and the entire mixture lyophilised.

The dry cellulose material was suspended in 2ml of butanol/ethanol/water (B:W:E) (4:1:1) and applied gently and evenly to the top of the packed bed. The remaining material was washed in using a further 2ml of the solvent. The solvent level was again dropped to the bed level before commencing pumping with B:W:E (4:1:1) at 5 ml/min. Fractions were collected in glass vessels as follows, either by hand into flasks or using a Gilson model 204 fraction collector set to 1 minute/tube:

Butanol/methanol/water (4:1:1)	150ml
Methanol	50ml
50% aqueous methanol	10 x 5ml fractions
Water	20 x 5ml fractions
HCl(aq.) pH 1.3	10 x 5ml fractions
HCl(aq.) pH 1.3	75ml

The samples were evaporated to dryness using a rotary evaporator or Speedvac at below 30°C. Samples were dissolved in 200µl of water and stored at -20°C.

#### **Preparation of conditioned medium (CM) from H4IIE cells**

(a) H4IIE cells were cultured on 75 cm<sup>2</sup> Falcon cap vented tissue culture flasks at cell density of 2-6 x 10<sup>4</sup> cells/cm<sup>2</sup> using DMEM (Gibco Cat. No. 31885), supplemented at 5% with a 1:1 mixture of foetal calf serum and heat inactivated calf serum and incubate at

37°C, 5% CO<sub>2</sub> atmosphere until 100% confluence.

(b) At confluence (15-17 x10<sup>6</sup> cells/T75 flask), the cells were washed twice using 15-20 mL Hank's Balance Salt Solution pH 7.4 (HBSS, Gibco Cat No. 14174-053) and 5ml Trypsin-EDTA solution (Sigma Cat. No. T 4171) was added. The excess of Trypsin was then removed, leaving in the flask only 2 ml of liquid which was then incubated for 10 min.

(c) When the cells detached, 8 ml of growth medium was added and the mixture was centrifuged for 5 min at 1000 rpm. The supernatant was discharged and the pellet resuspended by adding 10 ml growth medium. The cell suspension was transferred into a sterile 25 ml universal container, 10 ml of the same medium was added, the cap closed tightly and the container rocked several times to produce a homogeneous cell suspension.

(d) The cells were subcultured 1/10 or 1/20 (1-2.5 x 10<sup>4</sup>/cm<sup>2</sup>) in 75 cm<sup>2</sup> Falcon cap vented flask, using the same medium and incubation conditions described in step (a). When the cells seeded at 1/10 reached 70% confluence (11.5-12.0 x 10<sup>6</sup> cells/ T75 flask, normally 3 days after), the culture was washed three times with 20 ml serum free DMEM and then incubated for 3 hours. This procedure was repeated twice.

(e) The culture was incubated for 48 hr at 37°C, 5% CO<sub>2</sub> atmosphere, and then the conditioned medium was transferred into a centrifuge tube, and cell debris removed by centrifugation at 1000g for 10 min at 4°C and then at 105,000 g for 60 min at 4°C. The supernatant was sterilized by filtration and stored at -80°C.

**Biosynthetic labelling and extraction of conditioned medium**

(a) H4IIE cells grown to 50-60% confluence in T75 cap vented flask Falcon (Falcon Cat. No F3111) ( $8-9 \times 10^6$  cells/T75 flask) in DMEM medium, supplemented with 5% foetal calf serum and 5% heat inactivated calf serum, were washed twice using HBSS at 37°C. 10 mL of fresh growth medium was added and then 250 mCi of the  $^3\text{H}$ -labelled precursors (Glucosamine, Galactose, Mannose and *myo*-Inositol). The culture was incubated at 37°C, 5%  $\text{CO}_2$  atmosphere for 24 hours.

(b) After 24 hours, the cells were washed three times as described in step (d) above and the cells incubated and the medium harvested as in step (e).

(c) The supernatants obtained were adjusted to pH 3.0 with HCl (c), and prewashed activated charcoal (25 mg/mL) added and stirred at 4°C for 30 min. The suspension was transferred into centrifuge tubes and the charcoal spun down by centrifugation at 20,000 *g* for 30 min at 4°C.

(d) The supernatant was sterilized using a 0.2  $\mu\text{m}$  pore size filter and stored at 4°C. If it was not required for immediate use, it was freeze-dried and kept at -80°C until needed.

**Bioactivity assay of H4IIE conditioned medium by measuring the proliferation of FaO cells**

(a) FaO cells grown at 60-70% confluence in T75 Falcon cap-vented tissue culture flasks Gibco Cat.No F3111 with RPMI-1640 (Gibco Cat. No. 21875), supplemented at 5% with a 1:1 mixture of foetal calf serum and heat inactivated calf serum were washed twice with 20 ml of HBSS pH 7.4

(Gibco Cat. No. 14174). The cells were detached with Trypsin-EDTA solution (Sigma Cat. No. T4171) as described in steps (b) and (c) of "Preparation of conditioned medium from H4IIE" protocol set out above.

(b) The cell suspension was counted twice and the required volume to dilute the suspension at a density of  $2.5\text{--}3.0 \times 10^3$  cell/ml was calculated. The calculated volume of growth medium was added and the cells were transferred into a sterile 25 ml universal container. The container was rocked gently several times to produce a homogenous cell suspension.

(c) The cells were plated in a 96-wells Falcon U bottom shape microwell plate by adding 100  $\mu$ l of cell suspension per well and incubated at 37°C in a 5% CO<sub>2</sub> atmosphere incubator. After 24 hours, each well was washed three times with 100  $\mu$ l of serum free medium and incubates for a further 24 hours.

(d) The medium was replaced by adding serum free medium and the cells incubated for three additional hours. Meanwhile, the IPG samples or medium supplementation at different concentrations (ranging from 1% to 20.0%) of H4IIE conditioned medium were prepared. 100  $\mu$ l serum free medium was added to the controls, 100  $\mu$ l completed growth medium was added to the positive controls and 100  $\mu$ l of medium supplemented with H4IIE conditioned medium.

(e) The cells were incubated at 37°C in a 5% CO<sub>2</sub> atmosphere incubator for 18 hours and then 1 mCi <sup>3</sup>H-thymidine was added to each well. After 4 hours incubation, the radioactive medium was removed and replaced with 50  $\mu$ l trypsin-EDTA solution. The cells were incubated for 10 min and the DNA collected on

filters (Helis Bio Ltd. Cat No 11731) using a cell harvester (SKATRON 12 well/cell harvester). The filters were transferred to scintillation vials, 2 ml of scintillation cocktail was added to each vial and counted for one minute in a Beckman scintillation counter.

### Assays

Phosphate analysis and PDH activation assays were carried out as described in Caro et al, 1997.

### Results

#### Fractionation of conditioned medium by cellulose column chromatography

Conditioned medium biosynthetically labelled with  $^3\text{H}$  myo-inositol (squares), glucosamine (circles) or galactose (open circles) at  $1.35\text{E}5$ ,  $2.85\text{E}5$  and  $2.50\text{E}5$  cpm respectively, obtained as described in Methods, was separated by cellulose column chromatography, 5 ml fractions were collected and 200  $\mu\text{l}$  counted in a Beckman liquid scintillation counter. The results are presented in Figure 1 as counts per minute (cpm) per fraction. The arrows indicate the solvent system used at a particular fraction. The results in Figure 1 show that these radioactive components are incorporated into TAF fractions obtained from the supernatant and that the TAF fractions can be isolated by the same procedures as IPGs.

#### Effects on DNA synthesis of conditioned medium

Conditioned medium at two different concentrations (10% and 20%) was assayed for stimulating activity in test Fao cells, as under Methods. The fractions obtained by purification of conditioned medium (2 ml) by cellulose column chromatography were concentrated to dryness, dissolved in water (200  $\mu\text{l}$ ), and also assessed for

activity (4  $\mu$ l). The results are presented in Figure 2 as radioactivity (cpm) obtained after incorporation of  $^3$ H-thymidine into DNA, for control (no serum addition), FCS (5% foetal calf serum + 5% foetal bovine serum addition), and the fractions obtained. The arrows indicate the eluent system used at a particular fraction. The results show that some of the fractions, and in particular fraction 21 causes proliferation of Fao cells as does the addition of conditioned medium.

#### **Phosphate analysis of conditioned medium**

Conditioned medium (2 ml) was fractionated by column chromatography using cellulose as described under methods. Fractions (5 ml) were collected, concentrated to dryness, dissolved in water (200  $\mu$ l) and a portion (10  $\mu$ l) was assayed for phosphate as described in Caro et al, 1997. Briefly, samples were evaporated to dryness and hydrolized with perchloric acid (70% by volume) at 180°C for 30 min. After cooling at room temperature, distilled water (250  $\mu$ l) was added. Ammonium molybdate and ascorbic acid were sequentially added, yielding final concentrations of 3 and 72 mM, respectively. Colour development was achieved by heating at 95°C for 15 min. Optical absorbance was measured at 650 nm. The results are presented in Figure 3 as OD obtained per fraction. Arrows indicate the eluent system used at a particular fraction. The results show that the fractions co-purifying with TAF activity contain phosphate, supporting the fact that TAFs are IPGs.

#### **Effect on the proliferation of FaO cells of conditioned medium treated with anti-IPG monoclonal antibodies**

Test FaO cells were used to measure the stimulating activity of conditioned medium as described in methods, in the presence of the anti-IPG monoclonal antibodies



2D1, 5H6 and 2F1 at a concentration of 1 µg per well. The results in Figure 4 are presented as radioactivity (cpm) obtained after incorporation of <sup>3</sup>H-thymidine into DNA, for control (no serum addition), FCS (5% foetal calf serum + 5% foetal bovine serum addition) and samples containing the antibodies. The results show that all three antibodies antagonise the proliferating activity caused by the addition of conditioned medium to the Fao cells, and that antibody 2F1 had the greatest inhibitory effect.

#### **Rat liver IPGs A and P fractionation profiles**

The IPGs obtained from two rat livers were fractionated using cellulose column chromatography as described in Methods. The fractions obtained were evaporated to dryness, redissolved in water (200 µl), and a portion of the solution (1.25 µl) assayed for biological activity in triplicates. The results are shown as radioactivity (cpm) obtained after incorporation of <sup>3</sup>H-thymidine into DNA of 3T3EFGTR17 cells, for control (no serum addition), FCS (10% foetal calf addition), and fractions. All fractions were assayed at a final concentration of 1/80, except for fraction 26 of IPG-P (Figure 5) which was also tested at a final concentration of 1/40 and 1/160. All fractions of the IPG-A (Figure 6) were tested at a final concentration of 1/80. The arrows indicate the eluent system used at a particular fraction. The results indicate that cellulose chromatography is an effective technique for the isolation and purification of IPGs, e.g. IPGs obtained from natural source materials.

#### **PDH activity of Fraction 26 of IPG-P type**

PDH activity was measured as described in Caro et al, 1997. A portion (10 ml) of fractions 22, 26 and 27 was assayed. The result is presented as activation of the PDH complex expressed as units per gram of tissue. One

unit of IPG PDH activity is the amount required to increase the basal rate of NADH production by 50%.

Fraction 22 = 0.123 units/g

Fraction 26 = 2.09 units/g

Fraction 27 = 0.523 units/g.

The results show that the IPGs purified from rat liver using cellulose chromatography have a characteristic P-type IPG biological activity.

#### **Phosphate analysis of rat liver IPG-P**

The IPG-P obtained from two rat livers was fractionated by column chromatography using cellulose as described under Methods. Fractions (5 ml) were collected, concentrated to dryness, dissolved in water (200  $\mu$ l) and a portion (100  $\mu$ l) was assayed for phosphate as described in Caro et al, 1997. Each fraction was evaporated to dryness and hydrolized with perchloric acid (70% by volume) at 180°C for 30 min. After cooling at room temperature, distilled water (250  $\mu$ l) was added. Ammonium molybdate and ascorbic acid were sequentially added, yielding final concentrations of 3 and 72 mM, respectively. Colour development was achieved by heating at 95°C for 15 min. Optical absorbance was measured at 650 nm. The results in figure 8 are presented as OD obtained per fraction. Arrows indicate the eluent system used at a particular fraction. The results show that the P-type IPGs purified using cellulose chromatography contain phosphate.

#### **Deposits**

The deposit of hybridomas 2F7, 2D1 and 5H6 in support of this application was made at the European Collection of Cell Cultures (ECACC) under the Budapest Treaty by

Rademacher Group Limited (RGL), The Windeyer Building, 46  
Cleveland Street, London W1P 6DB, UK. The deposits have  
been accorded accession numbers accession numbers  
98051201, 98031212 and 98030901 on 12 May 1998 ('201) and  
5 9 March 1998 ('212 and '901). RGL give their unreserved  
and irrevocable consent to the the materials being made  
available to the public in accordance with appropriate  
national laws governing the deposit of these materials,  
such as Rules 28 and 28a EPC. The expert solution under  
10 Rule 28(4) EPC is also hereby requested.

11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379  
1380  
1381  
1382  
1383  
1384  
1385  
1386  
1387  
1388  
1389  
1390  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466  
1467  
1468  
1469  
1470  
1471  
1472  
1473  
1474  
1475  
1476  
1477  
1478  
1479  
1480  
1481  
1482  
1483  
1484  
1485  
1486  
1487  
1488  
1489  
1490  
1491  
1492  
1493  
1494  
1495  
1496  
1497  
1498  
1499  
1500  
1501  
1502  
1503  
1504  
1505  
1506  
1507  
1508  
1509  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1530  
1531  
1532  
1533  
1534  
1535  
1536  
1537  
1538  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1600  
1601  
1602  
1603  
1604  
1605  
1606  
1607  
1608  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637  
1638  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1800  
1801  
1802  
1803  
1804  
1805  
1806  
1807  
1808  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1820  
1821  
1822  
1823  
1824  
1825  
1826  
1827  
1828  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1870  
1871  
1872  
1873  
1874  
1875  
1876  
1877  
1878  
1879  
1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887  
1888  
1889  
1890  
1891  
1892  
1893  
1894  
1895  
1896  
1897  
1898  
1899  
1900  
1901  
1902  
1903  
1904  
1905  
1906  
1907  
1908  
1909  
1910  
1911  
1912  
1913  
1914  
1915  
1916  
1917  
1918  
1919  
1920  
1921  
1922  
1923  
1924  
1925  
1926  
1927  
1928  
1929  
1930  
1931  
1932  
1933  
1934  
1935  
1936  
1937  
1938  
1939  
1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  
2023  
2024  
2025  
2026  
2027  
2028  
2029  
2030  
2031  
2032  
2033  
2034  
2035  
2036  
2037  
2038  
2039  
2040  
2041  
2042  
2043  
2044  
2045  
2046  
2047  
2048  
2049  
2050  
2051  
2052  
2053  
2054  
2055  
2056  
2057  
2058  
2059  
2060  
2061  
2062  
2063  
2064  
2065  
2066  
2067  
2068  
2069  
2070  
2071  
2072  
2073  
2074  
2075  
2076  
2077  
2078  
2079  
2080  
2081  
2082  
2083  
2084  
2085  
2086  
2087  
2088  
2089  
2090  
2091  
2092  
2093  
2094  
2095  
2096  
2097  
2098  
2099  
2100  
2101  
2102  
2103  
2104  
2105  
2106  
2107  
2108  
2109  
2110  
2111  
2112  
2113  
2114  
2115  
2116  
2117  
2118  
2119  
2120  
2121  
2122  
2123  
2124  
2125  
2126  
2127  
2128  
2129  
2130  
2131  
2132  
2133  
2134  
2135  
2136  
2137  
2138  
2139  
2140  
2141  
2142  
2143  
2144  
2145  
2146  
2147  
2148  
2149  
2150  
2151  
2152  
2153  
2154  
2155  
2156  
2157  
2158  
2159  
2160  
2161  
2162  
2163  
2164  
2165  
2166  
2167  
2168  
2169  
2170  
2171  
2172  
2173  
2174  
2175  
2176  
2177  
2178  
2179  
2180  
2181  
2182  
2183  
2184  
2185  
2186  
2187  
2188  
2189  
2190  
2191  
2192  
2193  
219

**References:**

The references referred to herein are expressly incorporated by reference.

- 5 W098/11116 and W098/11117 (Rademacher Group Limited).

Rademacher et al, Brazilian J. Med. Biol. Res., 27:327-341, 1994.

- 10 Caro et al, Biochem. Mol. Med., 61:214-228, 1997.

Witters et al, J. Bio. Chem., 263:8027-8036, 1986.

methanol.

(11)  
(12)  
(13)  
(14)  
(15)  
(16)  
(17)  
(18)  
(19)  
(20)  
(21)  
(22)  
(23)  
(24)  
(25)  
(26)  
(27)  
(28)  
(29)  
(30)  
(31)  
(32)  
(33)  
(34)  
(35)  
(36)  
(37)  
(38)  
(39)  
(40)  
(41)  
(42)  
(43)  
(44)  
(45)  
(46)  
(47)  
(48)  
(49)  
(50)  
(51)  
(52)  
(53)  
(54)  
(55)  
(56)  
(57)  
(58)  
(59)  
(60)  
(61)  
(62)  
(63)  
(64)  
(65)  
(66)  
(67)  
(68)  
(69)  
(70)  
(71)  
(72)  
(73)  
(74)  
(75)  
(76)  
(77)  
(78)  
(79)  
(80)  
(81)  
(82)  
(83)  
(84)  
(85)  
(86)  
(87)  
(88)  
(89)  
(90)  
(91)  
(92)  
(93)  
(94)  
(95)  
(96)  
(97)  
(98)  
(99)  
(100)

Claims:

1. Use of a substance which is an inositolphosphoglycan (IPG) antagonist having the property of reducing tumour cell proliferation for the preparation of a medicament for the treatment of cancer.

2. The use of claim 1, wherein the IPG antagonist is:  
(a) a substance which is capable of inhibiting the release of IPGs; or,

10 (b) a substance capable of reducing the levels of IPGs by binding to the IPGs; or,  
(c) a substance which is a competitive agent which capable of reducing an effect of IPGs.

15 3. The use of claim 2, wherein the antagonist is a competitive IPG antagonist.

4. The use of claim 2, wherein the IPG antagonist is an anti-IPG antibody which is capable of specifically binding IPGs.

5. The use of claim 4, wherein the antibody capable of neutralising an activity of the IPGs.

25 6. The use of claim 5, wherein activity of the IPGs is the proliferation of tumour cells.

7. The use of any one of claims 4 to 6, wherein the antibody is a monoclonal antibody produced by hybridoma 2F7, 2D1 or 5H6, deposited at ECACC under accession numbers 98051201, 98031212 and 98030901.

8. The use of claim 2, wherein the antagonist is an inhibitor of glycosylphosphatidylinositol specific phospholipase type C (GPI-PLC).

9. Use of the presence or amount of inositolphosphoglycans (IPGs) in a sample from a patient for the diagnosis and/or prognosis of cancer.

10. A method for the diagnosis and/or prognosis of cancer, the method comprising determining the presence or amount of inositolphosphoglycans in a sample from a patient.

11. The method of claim 10, wherein the presence or amount of the IPGs is causing tumour cell proliferation.

12. The method of claim 10 or claim 11, wherein the method comprises the steps of:

(a) contacting a sample from a patient with a solid support having immobilised thereon a binding agent having binding sites which are capable of specifically binding to the IPGs with a sample from a patient under conditions in which the IPGs bind to the binding agent; and,

(b) determining the presence or amount of the IPGs bound to the binding agent.

13. The method of claim 12, wherein step (b) comprises (i) contacting the solid support with a developing agent which is capable of binding to occupied binding sites, unoccupied binding sites or the bound IPGs, the developing agent comprising a label and (ii) detecting the label to obtain a value representative of the presence or amount of the IPGs in the sample.

14. The method of claim 13, further comprising comparing the value with standards from healthy or cancerous tissues.

15. The method of claim 13 or claims 14, wherein the

label is a radioactive label, a chemiluminescent label, a fluorophor, a phosphor, a laser dye, a chromogenic dye, a macromolecular colloidal particle, a latex bead which is coloured, magnetic or paramagnetic, or an enzyme which catalyses a reaction producing a detectable result.

15. The method of any one of claims 12 to 15, wherein the binding agent immobilised on the solid support is an antibody which is capable of binding to the IPGs.

16. The method of any one of claims 12 to 16, wherein the binding agent is immobilised at a predefined location on the solid support.

17. Use of microcrystalline cellulose for purifying or isolating a P or A-type substance, wherein the substance is a cyclitol containing carbohydrate which is:

- (i) a P-type substance having the biological activity of activating pyruvate dehydrogenase (PDH) phosphatase; or,
- (ii) an A-type substance having the biological activity of inhibiting cAMP dependent protein kinase.

18. The use of claim 17, wherein the use involves contacting a sample containing P or A-type substance with a column containing cellulose and eluting the substance from the column.

19. A method of purifying or isolating a P or A-type substance, wherein the substance is a cyclitol containing carbohydrate which is:

- (i) a P-type substance having the biological activity of activating pyruvate dehydrogenase (PDH) phosphatase; or,
- (ii) an A-type substance having the biological



32


activity of inhibiting cAMP dependent protein kinase;  
wherein the method comprises:

- (a) loading a column containing microcrystalline cellulose with a sample containing the P or A-type substance so that P or A-type substance binds to the column; and,
- (b) eluting the P or A-type substance from the column.


20. The method of claim 19, further comprising the step of dissolving the sample containing the P or A-type substance in 4/1/1 butanol/water/ethanol (B:W:E) prior loading on the column.

21. The method of claim 19 or claim 20, further comprising the step of washing the column with B:W:E and methanol.

1/10




2/10




3/10

**FIGURE 2**  
Proliferation assay - FaO cells




4/10

**FIGURE 3**  
**H4 Conditioned Medium Fractionation - Phosphate Analysis**




[illegible]

**FIGURE 4**




6/10

**FIGURE 5**  
Proliferation Assay - Liver IPG P - Fibroblasts cells



7/10


**FIGURE 6 A**  
Proliferation Assay - Liver IPG A - Fibroblasts cells






8/10

**FIGURE 6B**  
Proliferation Assay - Liver IPG A - Fibroblasts cells




9/10

**FIGURE 7A**  
**Liver IPG P - Cellulose Purification- Phosphate Analysis**



10/10

**FIGURE 7B**  
Liver IPG P - Cellulose Purification- Phosphate Analysis



Attorney Docket No.: 10125-000300US  
 Client Reference No.: SJM/TF5938444

## DECLARATION

As a below named inventor, I declare that:

My residence, post office address and citizenship are as stated below next to my name; I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: **TREATMENT AND DIAGNOSIS OF CANCER USING INOSITOLPHOSPHOGLYCANS ANTAGONISTS** the specification of which        is attached hereto or        was filed on June 22, 2001 as Attorney Docket No. 10125-000300US, and was amended on                      (if applicable).

I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56. I claim foreign priority benefits under Title 35, United States Code, Section 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

## Prior Foreign Application(s)

Country	Application No.	Date of Filing	Priority Claimed Under 35 USC 119
PCT	PCT/GB99/04382	December 23, 1999	Yes
GB	9828564.6	December 23, 1998	Yes

I hereby claim the benefit under Title 35, United States Code § 119(a) of any United States provisional application(s) listed below:

Application No.	Filing Date



I claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, Section 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application No.	Date of Filing	Status
PCT/GB99/04382	December 23, 1999	Inactive

Attorney Docket No.: 1012E-000360US  
 Client Reference No.: 97K/EP-5931464

Full Name of Inventor 1:	Full Name: <b>RADEMACHER, Thomas William</b>		
Residence & Citizenship:	City: <b>Oxford</b>	State/Region/Country: <b>United Kingdom</b>	Country of Citizenship: <b>United States</b>
Post Office Address:	Post Office Address: <b>Forrester, The Ridgeway Bent, Hill, Oxford OX1 5QU United Kingdom</b>		
Full Name of Inventor 2:	Full Name: <b>CARO, Hugo</b>		
Residence & Citizenship:	City: <b>LONDON</b>	State/Region/Country: <b>United Kingdom</b>	Country of Citizenship: <b>Argentina</b>
Post Office Address:	Post Office Address: <b>82 TURNELL PARK RD, LONDON N7 0DT</b>		

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and that false oaths are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signature of Inventor 1:	Signature of Inventor 2:
	
RADEMACHER, Thomas William	CARO, Hugo
Date: <b>20/06/01</b>	Date: <b>21/06/01</b>